Philippe Moreau
Led MajesTEC-1 and CASSIOPEIA, bringing the first bispecific antibody and daratumumab quadruplets to myeloma.
Overview
Philippe Moreau (Nantes) was principal investigator of MajesTEC-1, the pivotal trial of teclistamab, the first BCMA-directed bispecific antibody approved for relapsed myeloma, and of CASSIOPEIA, which established daratumumab with bortezomib-thalidomide-dexamethasone in transplant-eligible patients. He has led IFM trials for two decades including the IFM 2009 transplant study and is a past chair of the IFM.
Pages like this
not linked directly; found by shared links- PersonAjai Chari
Shares CD38, CD3, Bispecific antibodies, T-cell engagers (bispecific) and the tags myeloma, bispecific.
- PersonMeletios A. Dimopoulos
Shares CD38, Multiple myeloma and the tags myeloma, trialist.
- PersonThierry Facon
Shares CD38, Multiple myeloma and the tags myeloma, trialist.
- ProductISB 2001
Shares CD38, Teclistamab, BCMA, Bispecific antibodies.
- PersonSaad Z. Usmani
Shares MajesTEC-1, Teclistamab, BCMA, T-cell engagers (bispecific).
- PersonMaría-Victoria Mateos
Shares CD38, Multiple myeloma and the tag myeloma.
- PersonMichael Dickinson
Shares CD3, Bispecific antibodies, T-cell engagers (bispecific) and the tag bispecific.
- CompanyCullinan Therapeutics
Shares CD3, BCMA, Bispecific antibodies, T-cell engagers (bispecific).